AAAAAA

   
Results: 1-25 | 26-50 | 51-75 | 76-100 | >>
Results: 1-25/193
LIQUID-CHROMATOGRAPHIC DETERMINATION OF IRINOTECAN AND 3 MAJOR METABOLITES IN HUMAN PLASMA, URINE AND FECES
Authors: SPARREBOOM A DEBRUIJN P DEJONGE MJA LOOS WJ STOTER G VERWEIJ J NOOTER K
Citation: A. Sparreboom et al., LIQUID-CHROMATOGRAPHIC DETERMINATION OF IRINOTECAN AND 3 MAJOR METABOLITES IN HUMAN PLASMA, URINE AND FECES, Journal of chromatography B. Biomedical sciences and applications, 712(1-2), 1998, pp. 225-235
DETERMINATION OF PACLITAXEL IN HUMAN PLASMA USING SINGLE SOLVENT-EXTRACTION PRIOR TO ISOCRATIC REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ULTRAVIOLET DETECTION
Authors: SPARREBOOM A DEBRUIJN P NOOTER K LOOS WJ STOTER G VERWEIJ J
Citation: A. Sparreboom et al., DETERMINATION OF PACLITAXEL IN HUMAN PLASMA USING SINGLE SOLVENT-EXTRACTION PRIOR TO ISOCRATIC REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ULTRAVIOLET DETECTION, Journal of chromatography B. Biomedical sciences and applications, 705(1), 1998, pp. 159-164
PHARMACOKINETICS AND BIOAVAILABILITY OF ORAL 9-AMINOCAMPTOTHECIN CAPSULES IN ADULT PATIENTS WITH SOLID TUMORS
Authors: SPARREBOOM A DEJONGE MJA PUNT CJA NOOTER K LOOS WJ PORRO MG VERWEIJ J
Citation: A. Sparreboom et al., PHARMACOKINETICS AND BIOAVAILABILITY OF ORAL 9-AMINOCAMPTOTHECIN CAPSULES IN ADULT PATIENTS WITH SOLID TUMORS, Clinical cancer research, 4(8), 1998, pp. 1915-1919
DISPOSITION OF CREMOPHOR EL IN HUMANS LIMITS THE POTENTIAL FOR MODULATION OF THE MULTIDRUG-RESISTANCE PHENOTYPE IN-VIVO
Authors: SPARREBOOM A VERWEIJ J VANDERBURG MEL LOOS WJ BROUWER E VIGANO L LOCATELLI A DEVOS AI NOOTER K STOTER G GIANNI L
Citation: A. Sparreboom et al., DISPOSITION OF CREMOPHOR EL IN HUMANS LIMITS THE POTENTIAL FOR MODULATION OF THE MULTIDRUG-RESISTANCE PHENOTYPE IN-VIVO, Clinical cancer research, 4(8), 1998, pp. 1937-1942
ORAL TOPOTECAN GIVEN ONCE OR TWICE-DAILY FOR 10 DAYS - A PHASE-I PHARMACOLOGY STUDY IN ADULT PATIENTS WITH SOLID TUMORS
Authors: GERRITS GJH BURRIS H SCHELLENS JHM ECKARDT JR PLANTING AST VANDERBURG MEL RODRIGUEZ GI LOOS WJ VANBEURDEN V HUDSON I FIELDS S VONHOFF DD VERWEIJ J
Citation: Gjh. Gerrits et al., ORAL TOPOTECAN GIVEN ONCE OR TWICE-DAILY FOR 10 DAYS - A PHASE-I PHARMACOLOGY STUDY IN ADULT PATIENTS WITH SOLID TUMORS, Clinical cancer research, 4(5), 1998, pp. 1153-1158
ORAL TOPOTECAN GIVEN ONCE OR TWICE-DAILY FOR 10 DAYS - A PHASE-I PHARMACOLOGY STUDY IN ADULT PATIENTS WITH SOLID TUMORS
Authors: GERRITS GJH BURRIS H SCHELLENS JHM ECKARDT JR PLANTING AST VANDERBURG MEL RODRIGUEZ GI LOOS WJ VANBEURDEN V HUDSON I FIELDS S VONHOFF DD VERWEIJ J
Citation: Gjh. Gerrits et al., ORAL TOPOTECAN GIVEN ONCE OR TWICE-DAILY FOR 10 DAYS - A PHASE-I PHARMACOLOGY STUDY IN ADULT PATIENTS WITH SOLID TUMORS, Clinical cancer research, 4(5), 1998, pp. 1153-1158
EFFECT OF FOOD ON THE PHARMACOKINETICS OF CAPECITABINE AND ITS METABOLITES FOLLOWING ORAL-ADMINISTRATION IN CANCER-PATIENTS
Authors: REIGNER B VERWEIJ J DIRIX L CASSIDY J TWELVES C ALLMAN D WEIDEKAMM E ROOS B BANKEN L UTOH M OSTERWALDER B
Citation: B. Reigner et al., EFFECT OF FOOD ON THE PHARMACOKINETICS OF CAPECITABINE AND ITS METABOLITES FOLLOWING ORAL-ADMINISTRATION IN CANCER-PATIENTS, Clinical cancer research, 4(4), 1998, pp. 941-948
EFFECT OF FOOD ON THE PHARMACOKINETICS OF CAPECITABINE AND ITS METABOLITES FOLLOWING ORAL-ADMINISTRATION IN CANCER-PATIENTS
Authors: REIGNER B VERWEIJ J DIRIX L CASSIDY J TWELVES C ALLMAN D WEIDEKAMM E ROOS B BANKEN L UTOH M OSTERWALDER B
Citation: B. Reigner et al., EFFECT OF FOOD ON THE PHARMACOKINETICS OF CAPECITABINE AND ITS METABOLITES FOLLOWING ORAL-ADMINISTRATION IN CANCER-PATIENTS, Clinical cancer research, 4(4), 1998, pp. 941-948
IRINOTECAN (CPT-11) METABOLISM AND DISPOSITION IN CANCER-PATIENTS
Authors: SPARREBOOM A DEJONGE MJA DEBRUIJN P BROUWER E NOOTER K LOOS WJ VANALPHEN RJ MATHIJSSEN RHJ STOTER G VERWEIJ J
Citation: A. Sparreboom et al., IRINOTECAN (CPT-11) METABOLISM AND DISPOSITION IN CANCER-PATIENTS, Clinical cancer research, 4(11), 1998, pp. 2747-2754
5 DAYS OF ORAL TOPOTECAN (HYCAMTIN(R)), A PHASE-I AND PHARMACOLOGICALSTUDY IN ADULT PATIENTS WITH SOLID TUMORS
Authors: GERRITS CJH BURRIS H SCHELLENS JHM PLANTING AST VANDENBURG MEL RODRIGUEZ GI VANBEURDEN V LOOS WJ HUDSON I FIELDS S VERWEIJ J VONHOFF DD
Citation: Cjh. Gerrits et al., 5 DAYS OF ORAL TOPOTECAN (HYCAMTIN(R)), A PHASE-I AND PHARMACOLOGICALSTUDY IN ADULT PATIENTS WITH SOLID TUMORS, European journal of cancer, 34(7), 1998, pp. 1030-1035
SEQUENCE-DEPENDENT PHARMACOKINETICS (PK) OF IFOSFAMIDE (I) COMBINED WITH DOCETAXEL (D)
Authors: SCHRIJVERS D PRONK L HIGHLEY M BRUNO M LOCCITONELLI D DEBRUIJN E VANOOSTEROM AT VERWEIJ J VERMORKEN JB
Citation: D. Schrijvers et al., SEQUENCE-DEPENDENT PHARMACOKINETICS (PK) OF IFOSFAMIDE (I) COMBINED WITH DOCETAXEL (D), European journal of cancer, 34, 1998, pp. 176-176
PHASE-II STUDY ON CISPLATIN AND IFOSFAMIDE IN RECURRENT HIGH-GRADE GLIOMAS
Authors: VANDENBENT MJ SCHELLENS JHM VECHT CJ SMIT PAES LOOSVELD OJL MA J TIJSSEN CC JANSEN RLH KROS JM VERWEIJ J
Citation: Mj. Vandenbent et al., PHASE-II STUDY ON CISPLATIN AND IFOSFAMIDE IN RECURRENT HIGH-GRADE GLIOMAS, European journal of cancer, 34(10), 1998, pp. 1570-1574
CORTICOSTEROID CO-MEDICATION DOES NOT REDUCE THE INCIDENCE AND SEVERITY OF NEUROTOXICITY INDUCED BY DOCETAXEL
Authors: PRONK LC HILKENS PHE VANDENBENT MJ VANPUTTEN WLJ STOTER G VERWEIJ J
Citation: Lc. Pronk et al., CORTICOSTEROID CO-MEDICATION DOES NOT REDUCE THE INCIDENCE AND SEVERITY OF NEUROTOXICITY INDUCED BY DOCETAXEL, Anti-cancer drugs, 9(9), 1998, pp. 759-764
GABA SENSITIVITY OF SPECTRALLY CLASSIFIED HORIZONTAL CELLS IN GOLDFISH RETINA
Authors: VERWEIJ J KAMERMANS M NEGISHI K SPEKREIJSE H
Citation: J. Verweij et al., GABA SENSITIVITY OF SPECTRALLY CLASSIFIED HORIZONTAL CELLS IN GOLDFISH RETINA, Visual neuroscience, 15(1), 1998, pp. 77-86
HIGH-DOSE IFOSFAMIDE FOR SOFT-TISSUE SARCOMAS - SET THE SCENE, OR SENESCENCE
Authors: VERWEIJ J
Citation: J. Verweij, HIGH-DOSE IFOSFAMIDE FOR SOFT-TISSUE SARCOMAS - SET THE SCENE, OR SENESCENCE, Annals of oncology, 9(8), 1998, pp. 807-809
FINAL RESULTS OF A RANDOMIZED PHASE-II STUDY OF THE EORTC SOFT-TISSUEAND BONE SARCOMA (STSBS) GROUP COMPARING 2 DIFFERENT IFOSFAMIDE (IF) REGIMENS IN CHEMOTHERAPY UNTREATED ADVANCED SOFT-TISSUE SARCOMA (STS) PATIENTS (PTS)
Authors: VANOOSTEROM AT KRZEMIENLECKI K NIELSEN OS JUDSON I MOURIDSEN HT SVANCAROVA L WOLL P SPOONER D HERMANS C VANGLABBEKE M VERWEIJ J
Citation: At. Vanoosterom et al., FINAL RESULTS OF A RANDOMIZED PHASE-II STUDY OF THE EORTC SOFT-TISSUEAND BONE SARCOMA (STSBS) GROUP COMPARING 2 DIFFERENT IFOSFAMIDE (IF) REGIMENS IN CHEMOTHERAPY UNTREATED ADVANCED SOFT-TISSUE SARCOMA (STS) PATIENTS (PTS), Annals of oncology, 9, 1998, pp. 552-552
PHASE-II RANDOMIZED STUDY COMPARING DOCETAXEL (T) TO DOXORUBICIN (D) IN PREVIOUSLY UNTREATED SOFT-TISSUE SARCOMAS (STS)
Authors: DIPAOLA ED JUDSON I LEE M RUKA W BUESA J COLEMAN R HERMANS C VANGLABBEKE M VERWEIJ J
Citation: Ed. Dipaola et al., PHASE-II RANDOMIZED STUDY COMPARING DOCETAXEL (T) TO DOXORUBICIN (D) IN PREVIOUSLY UNTREATED SOFT-TISSUE SARCOMAS (STS), Annals of oncology, 9, 1998, pp. 553-553
IS OBTENTION OF PARTIAL-RESPONSE (PR) IN FRONT-LINE CHEMOTHERAPY CRITICAL TO IMPROVE OUTCOME OF METASTATIC SOFT-TISSUE SARCOMA (MSTS) PATIENTS (PTS)
Authors: LECESNE A JUDSON J CROWTHER D SOMERS R TURSZ T KEIZER J VANHOESEL D BLAY Y FRISCH J VANGLABBEKE M VANOOSTEROM AT VERWEIJ J
Citation: A. Lecesne et al., IS OBTENTION OF PARTIAL-RESPONSE (PR) IN FRONT-LINE CHEMOTHERAPY CRITICAL TO IMPROVE OUTCOME OF METASTATIC SOFT-TISSUE SARCOMA (MSTS) PATIENTS (PTS), Annals of oncology, 9, 1998, pp. 556-556
A PHASE-II STUDY OF RALTITREXED (TOMUDEX) AS 2ND OR 3RD LINE TREATMENT FOR PATIENTS (PTS) WITH ADVANCED SOFT-TISSUE SARCOMAS (ASTS) REFRACTORY TO DOXORUBICIN CONTAINING REGIMENS
Authors: BLAY JY JUDSON I RODENHUIS S HERMANS C SMITH M VANGLABBEKE M VERWEIJ J
Citation: Jy. Blay et al., A PHASE-II STUDY OF RALTITREXED (TOMUDEX) AS 2ND OR 3RD LINE TREATMENT FOR PATIENTS (PTS) WITH ADVANCED SOFT-TISSUE SARCOMAS (ASTS) REFRACTORY TO DOXORUBICIN CONTAINING REGIMENS, Annals of oncology, 9, 1998, pp. 566-566
A PHASE-I STUDY OF TAXOTERE (T) AND GEMZAR (G) IN PATIENTS WITH ADVANCED SOLID TUMORS
Authors: PAWINSKIL A LOUWERENS M TONELLI D VANOOSTEROM AT VERWEIJ J
Citation: A. Pawinskil et al., A PHASE-I STUDY OF TAXOTERE (T) AND GEMZAR (G) IN PATIENTS WITH ADVANCED SOLID TUMORS, Annals of oncology, 9, 1998, pp. 665-665
EVALUATION OF RESPONSE TO TREATMENT IN SOLID TUMORS - CAN THE METHODOLOGY BE HARMONIZED AND SIMPLIFIED
Authors: THERASSE P EISENHAUER E WANDERS J VERWEIJ J VANGLABBEKE M VANOOSTEROM AT KAPLAN RS CHRISTIAN MC GWYTHER S ARBUCK SG
Citation: P. Therasse et al., EVALUATION OF RESPONSE TO TREATMENT IN SOLID TUMORS - CAN THE METHODOLOGY BE HARMONIZED AND SIMPLIFIED, Annals of oncology, 9, 1998, pp. 66-66
LIQUID-CHROMATOGRAPHIC DETERMINATION OF IRINOTECAN (CPT-11) AND ITS MAJOR METABOLITES IN HUMAN PLASMA, URINE AND FECES
Authors: SPARREBOOM A DEBRUIJN P DEJONGE MJA LOOS WJ NOOTER K STOTER G VERWEIJ J
Citation: A. Sparreboom et al., LIQUID-CHROMATOGRAPHIC DETERMINATION OF IRINOTECAN (CPT-11) AND ITS MAJOR METABOLITES IN HUMAN PLASMA, URINE AND FECES, Annals of oncology, 9, 1998, pp. 219-219
LIMITED-SAMPLING MODELS FOR 9-AMINOCAMPTOTHECIN PHARMACOKINETICS AFTER ORAL-DRUG ADMINISTRATION
Authors: SPARREBOOM A DEJONGE MJA PUNT CJA LOOS WJ DALLAIRE BK VERWEIJ J
Citation: A. Sparreboom et al., LIMITED-SAMPLING MODELS FOR 9-AMINOCAMPTOTHECIN PHARMACOKINETICS AFTER ORAL-DRUG ADMINISTRATION, Annals of oncology, 9, 1998, pp. 228-228
CLINICAL PHARMACOKINETICS OF ORAL 9-AMINOCAMPTOTHECIN IN PLASMA AND SALIVA - RELATIONSHIPS WITH HEMATOLOGIC TOXICITY
Authors: SPARREBOOM A DEJONGE MJA PUNT CJA LOOS WJ DALLAIRE BK VERWEIJ J
Citation: A. Sparreboom et al., CLINICAL PHARMACOKINETICS OF ORAL 9-AMINOCAMPTOTHECIN IN PLASMA AND SALIVA - RELATIONSHIPS WITH HEMATOLOGIC TOXICITY, Annals of oncology, 9, 1998, pp. 229-229
PHASE-I AND PHARMACOLOGICAL STUDY ON ORAL [PEG-1000] 9-AMINO-CAMPTOTHECIN (9-AC) IN PATIENTS WITH ADVANCED SOLID TUMORS
Authors: DEJONGE MJA PUNT CJA SPARREBOOM A LOOS WJ VANBEURDEN V PLANTING AST DALLAIRE B VERWEIJ J
Citation: Mja. Dejonge et al., PHASE-I AND PHARMACOLOGICAL STUDY ON ORAL [PEG-1000] 9-AMINO-CAMPTOTHECIN (9-AC) IN PATIENTS WITH ADVANCED SOLID TUMORS, Annals of oncology, 9, 1998, pp. 243-243
Risultati: 1-25 | 26-50 | 51-75 | 76-100 | >>